82930
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- age_years
- 8
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -3.453921603
- umap2_2d
- 2.427916002
- umap1_3d
- -0.689516756
- umap2_3d
- 3.221470169
- umap3_3d
- -1.724357759
- dataset
- EPN-Felix
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.370
- NOTCH_SIGNALING+0.310
- G2M_CHECKPOINT+0.300
- E2F_TARGETS+0.290
- PEROXISOME+0.220
- ESTROGEN_RESPONSE_LATE+0.210
- HEDGEHOG_SIGNALING+0.190
- BILE_ACID_METABOLISM+0.180
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.180
- WNT_BETA_CATENIN_SIGNALING+0.170
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.330
- PROTEIN_SECRETION-0.310
- CHOLESTEROL_HOMEOSTASIS-0.290
- ANGIOGENESIS-0.270
- MYC_TARGETS_V2-0.260
- ANDROGEN_RESPONSE-0.250
- UV_RESPONSE_DN-0.230
- UNFOLDED_PROTEIN_RESPONSE-0.210
- DNA_REPAIR-0.200
- MYC_TARGETS_V1-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_ZVWE73JZ | high-grade glioma | — | 0.684 |
| 2 | MNG340 | — | — | 0.654 |
| 3 | BS_V3Z3DB4N | high-grade glioma | — | 0.617 |
| 4 | MNG1086 | — | — | 0.610 |
| 5 | SRR33532783 | — | C | 0.592 |
| 6 | BS_3MS8WVNR | high-grade glioma | — | 0.583 |
| 7 | s0099994 | — | — | 0.580 |
| 8 | MNG222 | — | — | 0.570 |
| 9 | MDT-AP-2806 | Med | Medulloblastoma | 0.559 |
| 10 | MNG1292 | — | — | 0.558 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.210 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.180 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.050 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.010 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.010 | Idelalisib | — uncovered |